Log In
BCIQ
Print this Print this
 

IV tramadol

  Manage Alerts
Collapse Summary General Information
Company Revogenex Inc.
DescriptionIV formulation of a synthetic opioid
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat post-operative pain
Regulatory Designation
PartnerAvenue Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$2.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/18/2015

Undisclosed

$2.0M

Undisclosed

Get a free BioCentury trial today